Association Between Perioperative Platelet Function and Major Adverse Perioperative Events
This study will examine the degree of blood thinning (platelet function) in patients coming for non-cardiac surgery on antiplatelet agents using platelet function tests called thromboelastography (TEG) and platelet mapping assay (PMA) and major cardiac complications that occur any time after surgery (perioperative).
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Association Between Perioperative Platelet Inhibition (Function) and Major Adverse Perioperative Cardiac Events in Post Percutaneous Coronary Intervention Patients Undergoing Non-cardiac Surgery|
- Relationship between platelet function and MACE during the perioperative period [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Association of MACE with perioperative platelet function as measured by TEG and PMA [ Time Frame: 1 month ] [ Designated as safety issue: No ]
|Study Start Date:||March 2009|
|Estimated Study Completion Date:||June 2015|
|Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
Patients with PCI on blood thinners
Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
Procedure: Blood drawn
Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
Patients who have had stents in their coronary arteries (PCI) have to stay on antiplatelet agents to prevent clotting of their stents. These patients often require non-cardiac surgery (NCS) at some stage after their PCI. The rate of major cardiac complications (MACE)in this population is very high and it is unclear why they are at higher risk than the general population. It is possible their antiplatelet is not adequate, or that surgery causes them to be more clot prone. This is a prospective, multicentre observational study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00901030
|Hamilton Health Sciences|
|Hamilton, Ontario, Canada, L8L 2X2|
|London Health Sciences Centre|
|London, Ontario, Canada, N6A 5A5|
|University Health Network|
|Toronto, Ontario, Canada, M5G 2C4|
|Principal Investigator:||Summer Syed, M.D.||Hamilton Health Sciences Corporation|